Literature DB >> 29721389

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Diana Groza1,2, Sebastian Gehrig3, Pavol Kudela4, Martin Holcmann1, Christine Pirker1, Carina Dinhof1, Hemma H Schueffl1,2, Marek Sramko4, Julia Hoebart3, Fatih Alioglu3, Michael Grusch1, Manfred Ogris3, Werner Lubitz4, Bernhard K Keppler5,2, Irena Pashkunova-Martic5, Christian R Kowol5,2, Maria Sibilia1, Walter Berger1,2, Petra Heffeter1,2.   

Abstract

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality worldwide. At late stage of the disease CRC often shows (multiple) metastatic lesions in the peritoneal cavity which cannot be efficiently targeted by systemic chemotherapy. This is one major factor contributing to poor prognosis. Oxaliplatin is one of the most commonly used systemic treatment options for advanced CRC. However, drug resistance - often due to insufficient drug delivery - is still hampering successful treatment. The anticancer activity of oxaliplatin includes besides DNA damage also a strong immunogenic component. Consequently, the aim of this study was to investigate the effect of bacterial ghosts (BGs) as adjuvant immunostimulant on oxaliplatin efficacy. BGs are empty envelopes of gram-negative bacteria with a distinct immune-stimulatory potential. Indeed, we were able to show that the combination of BGs with oxaliplatin treatment had strong synergistic anticancer activity against the CT26 allograft, resulting in prolonged survival and even a complete remission in this murine model of CRC carcinomatosis. This synergistic effect was based on an enhanced induction of immunogenic cell death and activation of an efficient T-cell response leading to long-term anti-tumor memory effects. Taken together, co-application of BGs strengthens the immunogenic component of the oxaliplatin anticancer response and thus represents a promising natural immune-adjuvant to chemotherapy in advanced CRC.

Entities:  

Keywords:  adjuvant immunotherapy; bacterial ghosts; colon cancer; immunogenic cell death; oxaliplatin; peritoneal carcinomatosis

Year:  2018        PMID: 29721389      PMCID: PMC5927527          DOI: 10.1080/2162402X.2018.1424676

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  82 in total

Review 1.  Recognition of pathogen-associated molecular patterns by TLR family.

Authors:  Shizuo Akira; Hiroaki Hemmi
Journal:  Immunol Lett       Date:  2003-01-22       Impact factor: 3.685

2.  Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli.

Authors:  A Witte; G Wanner; M Sulzner; W Lubitz
Journal:  Arch Microbiol       Date:  1992       Impact factor: 2.552

Review 3.  Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.

Authors:  Reshma Singh; Anu Wallecha
Journal:  Hum Vaccin       Date:  2011-05-01

Review 4.  Immunology of the peritoneal cavity: relevance for host-tumor relation.

Authors:  B Melichar; R S Freedman
Journal:  Int J Gynecol Cancer       Date:  2002 Jan-Feb       Impact factor: 3.437

Review 5.  Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.

Authors:  Virgil Schijns; Eric Tartour; Jaroslav Michalek; Apostolos Stathopoulos; Neringa T Dobrovolskienė; Marius M Strioga
Journal:  Cytotherapy       Date:  2013-11-23       Impact factor: 5.414

Review 6.  Using Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Kristen A Marrone; Julie R Brahmer
Journal:  Oncology (Williston Park)       Date:  2016-08       Impact factor: 2.990

Review 7.  The spleen in local and systemic regulation of immunity.

Authors:  Vincenzo Bronte; Mikael J Pittet
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

8.  Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.

Authors:  Gabriel Bricard; Valerie Cesson; Estelle Devevre; Hanifa Bouzourene; Catherine Barbey; Nathalie Rufer; Jin S Im; Pedro M Alves; Olivier Martinet; Nermin Halkic; Jean-Charles Cerottini; Pedro Romero; Steven A Porcelli; H Robson Macdonald; Daniel E Speiser
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

9.  In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases.

Authors:  Elisabeth Stein; Aleksandra Inic-Kanada; Sandra Belij; Jacqueline Montanaro; Nora Bintner; Simone Schlacher; Ulrike Beate Mayr; Werner Lubitz; Marijana Stojanovic; Hristo Najdenski; Talin Barisani-Asenbauer
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-24       Impact factor: 4.799

10.  Comparison of Fenestra LC, ExiTron nano 6000, and ExiTron nano 12000 for micro-CT imaging of liver and spleen in mice.

Authors:  Hanne Boll; Giovanna Figueiredo; Teresa Fiebig; Stefanie Nittka; Fabian Doyon; Hans Ulrich Kerl; Ingo Nölte; Alex Förster; Martin Kramer; Marc A Brockmann
Journal:  Acad Radiol       Date:  2013-09       Impact factor: 3.173

View more
  8 in total

1.  Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

Authors:  B Brett Finlay; Romina Goldszmid; Kenya Honda; Giorgio Trinchieri; Jennifer Wargo; Laurence Zitvogel
Journal:  Nat Rev Immunol       Date:  2020-07-13       Impact factor: 53.106

Review 2.  The bacterial instrument as a promising therapy for colon cancer.

Authors:  Atieh Yaghoubi; Majid Khazaei; Amir Avan; Seyed Mahdi Hasanian; Saman Soleimanpour
Journal:  Int J Colorectal Dis       Date:  2020-03-04       Impact factor: 2.571

3.  Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells.

Authors:  Nessrin Saleh; Hoda E Mahmoud; Hoda Eltaher; Maged Helmy; Labiba El-Khordagui; Ahmed A Hussein
Journal:  Probiotics Antimicrob Proteins       Date:  2022-08-28       Impact factor: 5.265

Review 4.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

Review 5.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

Review 6.  Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.

Authors:  Marine Fidelle; Satoru Yonekura; Marion Picard; Alexandria Cogdill; Antoine Hollebecque; Maria Paula Roberti; Laurence Zitvogel
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 7.  The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?

Authors:  Jiayao Ma; Lingjuan Huang; Die Hu; Shan Zeng; Ying Han; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2021-10-16

Review 8.  Bacteria from Infectious Particles to Cell Based Anticancer Targeted Drug Delivery Systems.

Authors:  Mounir M Salem-Bekhit; Abdullah M E Youssof; Fars K Alanazi; Fadilah Sfouq Aleanizy; Alsuwyeh Abdulaziz; Ehab I Taha; Amro Abd Al Fattah Amara
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.